|
| 36082904 | Comprehensive Landscape of Cyclin Pathway Gene Alterations and Co-occurrence with FGF/FGFR Aberrations Across Urinary Tract Tumors. | Oncologist | 2023 |
| 37797367 | Gene partners of the EWSR1 fusion may represent molecularly distinct entities. | Transl Oncol | 2023 |
| 36862145 | POU2AF3-rearranged sarcomas: A novel tumor defined by fusions of EWSR1 or FUS to a gene formerly designated COLCA2. | Genes Chromosomes Cancer | 2023 |
| 35468996 | Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomas. | NPJ Precis Oncol | 2022 |
| 35705558 | Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. | Nat Commun | 2022 |
| 32885893 | Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large-Scale Data to Inform Therapeutic Directions. | Oncologist | 2021 |
| 33522043 | Landscape of Cyclin Pathway Genomic Alterations Across 5,356 Prostate Cancers: Implications for Targeted Therapeutics. | Oncologist | 2021 |
| 33610559 | Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach. | J Invest Dermatol | 2021 |
| 34021224 | Multiscale-omic assessment of EWSR1-NFATc2 fusion positive sarcomas identifies the mTOR pathway as a potential therapeutic target. | NPJ Precis Oncol | 2021 |
| 31604903 | The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. | Oncologist | 2020 |
| 31663661 | Genomic analysis reveals low tumor mutation burden which may be associated with GNAQ/11 alteration in a series of primary leptomeningeal melanomas. | Pigment Cell Melanoma Res | 2020 |
| 32923870 | Identifying Opportunities and Challenges for Patients With Sarcoma as a Result of Comprehensive Genomic Profiling of Sarcoma Specimens. | JCO Precis Oncol | 2020 |
| 32393201 | Recurrent secondary genomic alterations in desmoplastic small round cell tumors. | BMC Med Genet | 2020 |
| 30025711 | Genomic Characterization of Testicular Germ Cell Tumors Relapsing After Chemotherapy. | Eur Urol Focus | 2020 |
| 30659078 | Genomic Features for Therapeutic Insights of Chemotherapy-Resistant, Primary Mediastinal Nonseminomatous Germ Cell Tumors and Comparison with Gonadal Counterpart. | Oncologist | 2019 |
| 31577358 | Common Secondary Genomic Variants Associated With Advanced Epithelioid Hemangioendothelioma. | JAMA Netw Open | 2019 |
| 31258846 | Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. | Oncotarget | 2019 |
| 31189996 | Clinical, pathological, and genomic features of EWSR1-PATZ1 fusion sarcoma. | Mod Pathol | 2019 |
| 31218271 | Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors. | JCO Precis Oncol | 2019 |
| 31019022 | Degree of <i>MDM2</i> Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma. | Oncologist | 2019 |
| 30541756 | <i>BRCA1/2</i> Functional Loss Defines a Targetable Subset in Leiomyosarcoma. | Oncologist | 2019 |
| 30582752 | Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities. | Cancer | 2019 |
| 28753770 | Molecular Characterization of Bladder Cancer in Smokers versus Nonsmokers. | Eur Urol Focus | 2018 |
| 32913992 | <i>BRAF</i> in Lung Cancers: Analysis of Patient Cases Reveals Recurrent <i>BRAF</i> Mutations, Fusions, Kinase Duplications, and Concurrent Alterations. | JCO Precis Oncol | 2018 |
| 32913983 | Genomic Landscape of Appendiceal Neoplasms. | JCO Precis Oncol | 2018 |
| 30099373 | Genomic Profiling in Patients With Malignant Peripheral Nerve Sheath Tumors Reveals Multiple Pathways With Targetable Mutations. | J Natl Compr Canc Netw | 2018 |
| 30006421 | Response to Checkpoint Inhibitor Therapy in Advanced Classic Kaposi Sarcoma: A Case Report and Immunogenomic Study. | J Natl Compr Canc Netw | 2018 |
| 28974397 | Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI-1)-Deficient Carcinomas of the Urinary System. | Clin Genitourin Cancer | 2018 |
| 28753842 | Molecular and Genomic Profiling to Identify Actionable Targets in Chromophobe Renal Cell Cancer. | Eur Urol Focus | 2018 |
| 28868010 | Clinical Benefit from Trametinib in a Patient with Appendiceal Adenocarcinoma with a <i>GNAS R201H</i> Mutation. | Case Rep Oncol | 2017 |
| 28280620 | Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis. | J Gastrointest Oncol | 2017 |
| 28939679 | Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability. | Cancer Res | 2017 |
| 26937756 | Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials. | Int J Gynecol Cancer | 2016 |
| 26661118 | Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options. | J Surg Oncol | 2016 |
| 27388585 | Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19⿯784 Diverse Solid Tumors. | JAMA Oncol | 2016 |
| 25178641 | Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin. | Clin Genitourin Cancer | 2015 |
| 26380056 | Adenosquamous carcinoma of the pancreas: Molecular characterization of 23 patients along with a literature review. | World J Gastrointest Oncol | 2015 |
| 26320869 | Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers. | J Mol Diagn | 2015 |
| 26307625 | PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation. | Cancer Immunol Res | 2015 |
| 26715866 | Molecular Profiling of Refractory Adrenocortical Cancers and Predictive Biomarkers to Therapy. | Biomark Cancer | 2015 |
| 26051240 | Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications. | Clin Breast Cancer | 2015 |
| 26110571 | Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1. | Oncotarget | 2015 |
| 25906748 | Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets. | Oncotarget | 2015 |
| 25712293 | HER2 expression status in diverse cancers: review of results from 37,992 patients. | Cancer Metastasis Rev | 2015 |
| 25692060 | Metastatic Extramammary Paget's Disease of Scrotum Responds Completely to Single Agent Trastuzumab in a Hemodialysis Patient: Case Report, Molecular Profiling and Brief Review of the Literature. | Case Rep Oncol Med | 2015 |
| 25525849 | Highlights from the latest findings in tumor molecular profiling. | Future Oncol | 2014 |
| 25415047 | Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases. | Oncotarget | 2014 |
| 20197107 | Selective and potent furin inhibitors protect cells from anthrax without significant toxicity. | Int J Biochem Cell Biol | 2010 |
| 16386899 | Guanidinylated 2,5-dideoxystreptamine derivatives as anthrax lethal factor inhibitors. | Bioorg Med Chem Lett | 2006 |
| 17179036 | Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine. | Proc Natl Acad Sci U S A | 2006 |